Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market to Surpass US$ 2,075.34 Million by 2027
Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, by Drug Class (Pleuromutilin Antibiotic, Cephalosporin, Glycylcycline, Oxazolidinone, Ketolide, and Others), by Dose Form (Solution and Tablet), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 1,269.73 million in 2020 and is expected to exhibit a CAGR of 7.2% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
Launch of novel products by market players to augment the market growth
Key players in the market are focused on ‘regulatory product approval of novel products to address the critical unmet needs of patients. For instance, in August 2019, Nabriva Therapeutics, a spinoff of Novartis AG, received approval for Xenleta (lefamulin) by the U.S. Food and Drug Administration (FDA) for the treatment of community-acquired bacterial pneumonia (CABP) in adults. The drug has also gained the U.S. FDA’s Qualified Infectious Disease Product (QIDP) designation and is available in the U.S. market.
Moreover, increasing incidence of pneumococcal disease is expected to drive the market growth. For instance, according to the Centers for Disease Control and Prevention (CDC), 2017, pneumococcal pneumonia causes around 150,000 hospitalizations every year, which surges the market progression in the U.S. Additionally, children, as well as elderly, are at a higher risk of getting infected by pneumococcal disease, owing to the weak immune system. Thus, increasing cases of pneumonia across the globe will propel the community-acquired bacterial pneumonia (CABP) treatment drugs market growth.
Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it as a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus disease (COVID-19) has resulted in over 30.6 million infected individuals worldwide as of 21st September 2020.
COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channel, and by its financial impact on firms and financial markets. Due to lockdowns, several countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of such drugs from one place to another.
Moreover the COVID-19 pandemic has impacted the supply of raw materials and potent compounds which are used for manufacturing drugs such as community-acquired bacterial pneumonia (CABP) treatment drugs, which can hamper the market growth in the near future.
Browse 42 Market Data Tables and 26 Figures spread through 188 Pages and in-depth TOC on “Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market - by Drug Class (Pleuromutilin Antibiotic, Cephalosporin, Glycylcycline, Oxazolidinone, Ketolide, and Others), by Dose Form (Solution and Tablet), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Global Forecast to 2027”
To know the latest trends and insights prevalent in the global community-acquired bacterial pneumonia (CABP) treatment drugs market, click the link below:
Key players in the market are focusing on developing and launching products for the treatment of community acquired bacterial pneumonia (CABP). For instance, in February 2019, Paratek Pharmaceuticals, Inc. a biopharmaceutical company commercially launched NUZYRA (omadacycline), a modernized tetracycline for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI) in the U.S.
Key Takeaways of the Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market:
- The global community-acquired bacterial pneumonia (CABP) treatment drugs market is expected to exhibit a CAGR of 7.2% during the forecast period, owing to increasing incidence of community-acquired bacterial pneumonia, increasing R&D of community acquired bacterial pneumonia treatment products, and product launches. For instance, according to the Global Burden of Disease Study, an article published in the National Center for Biotechnology Information (NCBI) in November 2019, reports that globally, incidence of pneumonia is estimated to be between 1.5 and 14.0 cases per 1,000 person.
- Among drug class, pleuromutilin antibiotic segment held a dominant position in the community-acquired bacterial pneumonia (CABP) treatment drugs market in 2019, owing to its potent activity against bacteria
- Among dose form, tablet segment held a dominant position in the community-acquired bacterial pneumonia (CABP) treatment drugs market in 2019, as they potentially saves cost in the treatment.
- Among route of administration, oral segment held a dominant position in the community-acquired bacterial pneumonia (CABP) treatment drugs market in 2019, as their variable penetration to different target sites of infection, drug solubility, and extent of protein binding determines the strong effectiveness.
- Among distribution channel, hospital pharmacies segment held a dominant position in the community-acquired bacterial pneumonia (CABP) treatment drugs market in 2019, as majority of the community-acquired bacterial pneumonia patients are registered at hospitals.
- Key players operating in the global community-acquired bacterial pneumonia (CABP) treatment drugs market include Nabriva Therapeutics, Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Bayer AG, Lupin Pharmaceuticals, Inc., Mylan N.V., Sanofi S.A., Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, and Basilea Pharmaceutica International AG.
Contact Us